|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Vermont |
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000223 |
The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.
Condition | Intervention | Phase |
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase II |
Drug Information available for: | Buprenorphine Buprenorphine hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control, Crossover Assignment |
Official Title: | Alternate-Day Buprenorphine Administration. Phase IV |
Ages Eligible for Study: | 20 Years to 49 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Vermont | |||||
Treatment Research Center | |||||
Burlington, Vermont, United States, 05401 |
National Institute on Drug Abuse (NIDA) |
University of Vermont |
Principal Investigator: | Warren Bickel, Ph.D. | University of Vermont |
Study ID Numbers: | NIDA-06969-5, R01-06969-5 |
First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000223 |
Health Authority: | United States: Federal Government |
|
|
|